On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma who have received one to three prior lines of therapy.
Read the FDA announcement.
Read the Sanofi announcement.
Posted 4/1/2021
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
